S&P 500 (NYSE:SPY) component Bristol-Myers Squibb Co. (NYSE:BMY) will unveil its latest earnings on Thursday, July 28, 2011. Bristol-Myers Squibb Company is a global company which develops, manufactures and sells pharmaceutical products. Johnson & Johnson Earnings Cheat Sheet: Margins Shrink For Fifth Straight Quarter as Profit Falls>>
Bristol-Myers Squibb Co. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net income of 55 cents per share, a rise of 1.9% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 54 cents. Between one and three months ago, the average estimate was unchanged, but has risen during the last month. For the year, analysts are projecting profit of $2.21 per share, a rise of 2.3% from last year.
Past Earnings Performance: The company topped estimates last quarter after missing forecasts the quarter prior. In the first quarter, it reported net income of 58 cents per share against a mean estimate of profit of 53 cents per share. In the fourth quarter of the last fiscal year, it missed forecasts by one cent.
Wall St. Revenue Expectations: On average, analysts predict $5.04 billion in revenue this quarter, a rise of 5.7% from the year ago quarter. Analysts are forecasting total revenue of $20.52 billion for the year, a rise of 5.3% from last year’s revenue of $19.48 billion.
Analyst Ratings: Analysts are bullish on Bristol-Myers Squibb as 13 analysts rate it as a buy, one rates it as a sell and 13 rate it as a hold.
The increase in profit in the first quarter breaks a streak of three consecutive quarters of year-over-year profit decreases. In the first quarter, net income rose 32.7% from the year earlier, while the figure dropped 94% in the fourth quarter of the last fiscal year, 1.8% in the third quarter of the last fiscal year and 5.7% in the second quarter of the last fiscal year.
The company’s revenue has now risen for two straight quarters. In first quarter, revenue increased 4.2% to $5.01 billion from the year earlier quarter. In the fourth quarter of the last fiscal year, the figure rose 74.9%.
Competitors to Watch: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Sanofi-Aventis SA (NYSE:SNY), Abbott Laboratories (NYSE:ABT), Novartis AG (NYSE:NVS), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), and AstraZeneca plc (NYSE:AZN).
Stock Price Performance: During May 25, 2011 to July 22, 2011, the stock price had risen $1.54 (5.5%) from $27.95 to $29.49. The stock price saw one of its best stretches over the last year between August 30, 2010 and September 13, 2010 when shares rose for 10-straight days, rising 5.1% (+$1.25) over that span. It saw one of its worst periods between January 3, 2011 and January 11, 2011 when shares fell for seven-straight days, falling 2.5% (-63 cents) over that span. Shares are up $3.96 (+15.5%) year to date.
(Source: Xignite Financials)